Yield of sputum culture and sensitivity in acute exacerbation of chronic obstructive pulmonary disease patients
DOI:
https://doi.org/10.59736/IJP.23.03.976Keywords:
Antibiotic Sensitivity, COPD, Chronic Obstructive Pulmonary Disease Exacerbation, Sputum CultureAbstract
Background: Acute exacerbations of chronic obstructive pulmonary disease (COPD) are frequently triggered by bacterial infections, leading to increased morbidity, mortality, and healthcare burden. Identification of causative organisms and their antibiotic sensitivity patterns is crucial for guiding empirical therapy, improving patient outcomes, and combating antimicrobial resistance. This study aim to determine the diagnostic yield of sputum culture and sensitivity in acute exacerbation of COPD patients and assess antimicrobial susceptibility patterns to guide targeted antibiotic therapy and promote antimicrobial stewardship.
Methods: This cross-sectional study was conducted in the Pulmonology Department, Khyber Teaching Hospital, Peshawar, from December 2024 to June 2025. A total of 135 patients, aged 18–80 years, diagnosed with COPD per GOLD criteria, were enrolled using non-probability consecutive sampling. The WHO sample size calculator (5% margin of error) determined the sample size. Exclusion criteria included recent antibiotic use (within 2 weeks), active tuberculosis, coexisting pulmonary diseases, inability to produce sputum, and immunocompromised states such as HIV/AIDS or immunosuppressive therapy.
Results: Of the 135 patients, sputum culture positivity was 71.7%, with all isolates being Gram-negative. The most frequent organisms were Escherichia coli and Citrobacter (17.4% each), followed by Klebsiella (13.8%) and Pseudomonas aeruginosa (8.7%). Acinetobacter and Enterobacter was least common (2.9% each). Highest sensitivities were observed for tigecycline (84.4%), amikacin (78.1%), ertapenem (70.8%), and Meropenem (66.7%), whereas ampicillin, co-amoxiclav, and ceftriaxone showed the highest resistance.
Conclusion: Gram-negative organisms, notably E. coli and Citrobacter, predominated in sputum cultures of COPD exacerbation patients. Tigecycline, amikacin, ertapenem, and Meropenem exhibited the best sensitivity profiles, while ampicillin, co-amoxiclav, and ceftriaxone showed marked resistance. Empirical treatment should focus on antibiotics active against these prevalent Gram-negative pathogens to optimize patient outcomes.
References
World Health Organization. Chronic obstructive pulmonary disease (COPD) [Internet]. Geneva: WHO; 2025 [cited 2025 Sep 1]. Available from: [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)](https://www.who.int/news-room/fact sheets/detail/chronic-obstructive-pulmonary-disease-%28copd%29)
Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415.
Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418-22.
Selvi I, Uma A, Edwin D. Bacteriological study of acute exacerbation of chronic obstructive pulmonary disease. J Popul Ther Clin Pharmacol. 2024;31(3):614-21.
Pavord ID, Jones PW, Burgel PR, Rabe KF, Wedzicha JA, Wouters EFM, et al. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11(Spec Iss):21-30.
Mendelson M, Matsoso MP. The World Health Organization global action plan for antimicrobial resistance. S Afr Med J. 2015;105(5):325.
Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M. Achieving global targets for antimicrobial resistance. Science. 2016;353(6302):874-5.
Miravitlles M, Anzueto A. Role of infection in exacerbations of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2015;21(3):278-83.
Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139-47.
Alobaidi NY, Alghamdi AA, Albarrak MM, Aldhahir AM, Alanazi AA, Alotaibi YM, et al. An overview of exacerbations of chronic obstructive pulmonary disease: can tests of small airways' function guide diagnosis and management? Ann Thorac Med. 2020;15(2):54-63.
Miravitlles M, Anzueto A. Chronic respiratory infection in patients with chronic obstructive pulmonary disease: what is the role of antibiotics? Int J Mol Sci. 2017;18(7):1344.
Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347(7):465-71.
Mussema A, Beyene G, Gashaw M. Bacterial isolates and antibacterial resistance patterns in a patient with acute exacerbation of chronic obstructive pulmonary disease in a tertiary teaching hospital, Southwest Ethiopia. Can J Infect Dis Med Microbiol. 2022;2022:9709253.
Samad A, Ahmed T, Rahim A, Khalil A, Ali I. Antimicrobial susceptibility patterns of clinical isolates of Pseudomonas aeruginosa isolated from patients of respiratory tract infections in a tertiary care hospital, Peshawar. Pak J Med Sci. 2017;33(3):670-4.
Danish I, Rehman S, Bibi M, Khan R. Bacterial etiology and antibiotic susceptibility patterns in acute exacerbations of chronic obstructive pulmonary disease: implications for targeted antimicrobial therapy. Pak J Chest Med. 2025;31(1):37-43.
Zohaib A, Khan FA, Khan I, Ahmad M, Khalid T, Malik T, et al. Antimicrobial susceptibility pattern among patients presenting with acute exacerbation of COPD. J Islamabad Med Dental Coll. 2020;9(1):23-7.
Dao DT, Le HY, Nguyen MH. Spectrum and antimicrobial resistance in acute exacerbation of chronic obstructive pulmonary disease with pneumonia: a cross-sectional prospective study from Vietnam. BMC Infect Dis. 2024;24:622.
Miah MAH, Mannan MA, Ali MMI, Khan MDJ, Hoque AFMA. Microbial patterns in acute exacerbation of chronic obstructive pulmonary disease at tertiary care. Int J Adv Med. 2024;11(4):309-13.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [Internet]. Bethesda: GOLD; 2025 [cited 2025 Sep 1]. Available from: [http://www.goldcopd.org](http://www.goldcopd.org)
Taddei L, Malvisi L, Hui DS, Malvaux L, Samoro RZ, Lee SH, et al. Airway pathogens detected in stable and exacerbated COPD in patients in Asia-Pacific. ERJ Open Res. 2022;8(3):0057-2022.
Halpin DMG, Singh D. What's new in the 2025 GOLD report. J Bras Pneumol. 2025;51(1):e20240412.
Huțanu D, Sárközi HK, Vultur MA, Sabău AH, Cocuz IG, Mărginean C, et al. Analyzing clinical parameters and bacterial profiles to uncover the COPD exacerbations: a focus on intensive care unit challenges. Medicina (Kaunas). 2025;61(4):669.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ejaz Ahmad, Hafizullah, Muhammad Ayaz, Hussain Ahmad, Said Ul Siyab, Syed Akmal Shah
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
